Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

6.29 

-0.31 -4.7%

as of Nov 15 '18

52 Week Range:

4.67 7.84


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Equity (BVPS) 0.37
0.83
0.84
1.20
1.25
1.30
1.49
1.52
2.10
2.40
2.56
growth rate 124.3% 1.2% 42.9% 4.2% 4.0% 14.6% 2.0% 38.2% 14.3% 6.7%
Earnings BIT 10.70
-11.30
9.10
-10.80
23.00
24.10
42.90
32.50
53.60
83.80
108.60
growth rate -100.0% 100.0% -100.0% 100.0% 4.8% 78.0% -24.2% 64.9% 56.3% 29.6%
Avg.PE 14.58
-21.10
40.49
67.11
75.76
71.94
80.65
75.33
41.03
0.78
31.63
growth rate -100.0% 100.0% 65.7% 12.9% -5.0% 12.1% -6.6% -45.5% -98.1% 3,955.1%
ROA 10.84
-6.30
3.53
2.30
2.94
3.14
3.88
3.82
5.51
2.73
1.03
growth rate -100.0% 100.0% -34.8% 27.8% 6.8% 23.6% -1.6% 44.2% -50.5% -62.3%
ROE 17.17
-9.78
5.28
3.03
3.66
3.92
5.06
5.21
7.53
3.68
1.34
growth rate -100.0% 100.0% -42.6% 20.8% 7.1% 29.1% 3.0% 44.5% -51.1% -63.6%
ROIC 12.84
-11.35
5.06
2.94
3.55
3.74
5.02
5.20
7.51
3.65
1.30
growth rate -100.0% 100.0% -41.9% 20.8% 5.4% 34.2% 3.6% 44.4% -51.4% -64.4%
Cur. Ratio 2.98
1.70
2.60
2.48
2.99
3.61
1.67
1.80
2.38
2.07
2.15
growth rate -43.0% 52.9% -4.6% 20.6% 20.7% -53.7% 7.8% 32.2% -13.0% 3.9%
Quick Ratio 2.91
1.44
2.32
1.82
2.33
3.25
1.29
1.43
1.98
1.70
1.81
growth rate -50.5% 61.1% -21.6% 28.0% 39.5% -60.3% 10.9% 38.5% -14.1% 6.5%
Leverage 1.56
1.55
1.45
1.25
1.25
1.25
1.34
1.38
1.36
1.34
1.27
growth rate -0.6% -6.5% -13.8% 0.0% 0.0% 7.2% 3.0% -1.5% -1.5% -5.2%
Balance Sheet Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Acct.Receivable 12.40
20.30
15.50
21.00
24.00
26.00
39.30
50.70
54.00
74.60
75.50
growth rate 63.7% -23.7% 35.5% 14.3% 8.3% 51.2% 29.0% 6.5% 38.2% 1.2%
Acct.Payable 8.00
6.00
9.00
14.00
10.80
16.00
14.20
20.30
growth rate -25.0% 50.0% 55.6% -22.9% 48.2% -11.3% 43.0%
Cur.Assets 72.20
118.30
113.10
130.00
174.00
237.00
146.20
207.60
297.50
342.30
408.00
growth rate 63.9% -4.4% 14.9% 33.9% 36.2% -38.3% 42.0% 43.3% 15.1% 19.2%
Total Assets 86.30
329.40
311.00
489.00
506.00
545.00
711.70
1,045.90
1,148.80
1,311.10
1,162.70
growth rate 281.7% -5.6% 57.2% 3.5% 7.7% 30.6% 47.0% 9.8% 14.1% -11.3%
Cash 57.20
78.20
82.60
64.00
107.00
159.00
38.20
73.80
140.40
155.50
210.00
growth rate 36.7% 5.6% -22.5% 67.2% 48.6% -76.0% 93.2% 90.2% 10.8% 35.1%
Inventory 0.00
10.50
9.60
20.00
22.00
23.00
27.00
40.50
46.50
58.40
61.00
growth rate -8.6% 108.3% 10.0% 4.6% 17.4% 50.0% 14.8% 25.6% 4.5%
Cur.Liabilities 24.20
69.70
43.40
52.00
58.00
66.00
87.80
115.60
125.00
165.50
190.10
growth rate 188.0% -37.7% 19.8% 11.5% 13.8% 33.0% 31.7% 8.1% 32.4% 14.9%
Liabilities 31.10
116.80
95.80
96.00
100.00
110.00
181.30
287.30
301.10
331.20
249.90
growth rate 275.6% -18.0% 0.2% 4.2% 10.0% 64.8% 58.5% 4.8% 10.0% -24.6%
LT Debt 0.00
1.30
0.60
3.00
0.00
0.00
0.00
growth rate -53.9% 400.0% -100.0%
Equity 55.20
212.60
215.20
392.30
406.20
434.60
530.40
758.60
847.70
979.90
914.70
growth rate 285.1% 1.2% 82.3% 3.5% 7.0% 22.0% 43.0% 11.8% 15.6% -6.7%
Common Shares 149.00
183.00
256.00
269.00
329.00
330.00
360.00
373.00
388.00
390.00
389.00
growth rate 22.8% 39.9% 5.1% 22.3% 0.3% 9.1% 3.6% 4.0% 0.5% -0.3%
Cash Flow Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Capital Expenditures 1.70
-1.20
3.00
11.00
4.00
8.00
11.60
9.80
6.20
8.90
10.40
growth rate -100.0% 100.0% 266.7% -63.6% 100.0% 45.0% -15.5% -36.7% 43.6% 16.9%
Cash Dividends 0.00 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA 13.40
-1.80
5.80
-12.00
47.00
56.00
48.50
47.50
95.60
74.20
120.70
growth rate -100.0% 100.0% -100.0% 100.0% 19.2% -13.4% -2.1% 101.3% -22.4% 62.7%
FCF per Share 0.08
-0.02
0.01
-0.12
0.01
0.17
0.10
0.13
0.09
0.22
0.22
growth rate -100.0% 100.0% -100.0% 100.0% 1,600.0% -41.2% 30.0% -30.8% 144.4% 0.0%
Sale Purchase of Stock 103.40
147.20
1.10
0.80
2.40
growth rate 42.4% -99.3% -27.3% 200.0%
FCF 11.00
-3.00
3.00
-33.00
38.00
45.00
36.00
36.00
65.00
65.00
109.00
growth rate -100.0% 100.0% -100.0% 100.0% 18.4% -20.0% 0.0% 80.6% 0.0% 67.7%
Income Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Sales 75.00
84.80
98.50
111.00
197.00
234.00
290.50
367.80
447.50
570.50
620.50
growth rate 13.1% 16.2% 12.7% 77.5% 18.8% 24.2% 26.6% 21.7% 27.5% 8.8%
Op.Income 8.50
-9.20
2.10
9.00
15.00
16.00
42.90
32.50
53.60
83.80
108.60
growth rate -100.0% 100.0% 328.6% 66.7% 6.7% 168.1% -24.2% 64.9% 56.3% 29.6%
IBT 10.70
-11.30
9.10
-10.80
23.00
24.10
33.30
26.70
57.50
31.60
-70.60
growth rate -100.0% 100.0% -100.0% 100.0% 4.8% 38.2% -19.8% 115.4% -45.0% -100.0%
Net Income 8.80
-13.10
11.30
9.00
15.00
16.00
24.30
33.60
60.50
33.60
15.00
growth rate -100.0% 100.0% -20.4% 66.7% 6.7% 51.9% 38.3% 80.1% -44.5% -55.4%
EPS 0.05
-0.07
0.04
0.03
0.04
0.05
0.07
0.09
0.15
0.08
0.03
growth rate -100.0% 100.0% -25.0% 33.3% 25.0% 40.0% 28.6% 66.7% -46.7% -62.5%
Gross Profit 42.40
47.70
65.70
79.00
143.00
167.00
197.40
254.00
308.20
391.60
434.80
growth rate 12.5% 37.7% 20.2% 81.0% 16.8% 18.2% 28.7% 21.3% 27.1% 11.0%
R&D 47.20
68.30
77.20
87.80
96.80
growth rate 44.7% 13.0% 13.7% 10.3%

Quarterly Statements

Item Name Mar '17 Jun '17 Sep '17 Dec '17 Mar '18
Earnings BIT 12.20
38.80
38.80
15.50
15.50
growth rate 218.0% 0.0% -60.1% 0.0%
Balance Sheet Mar '17 Jun '17 Sep '17 Dec '17 Mar '18
Acct.Receivable 74.60
128.20
128.20
75.50
75.50
growth rate 71.9% 0.0% -41.1% 0.0%
Acct.Payable 14.20
117.50
117.50
20.30
20.30
growth rate 727.5% 0.0% -82.7% 0.0%
Cur.Assets 342.30
412.00
412.00
408.00
408.00
growth rate 20.4% 0.0% -1.0% 0.0%
Total Assets 1,311.10
1,304.70
1,304.70
1,162.70
1,162.70
growth rate -0.5% 0.0% -10.9% 0.0%
Cash 155.50
226.50
226.50
210.00
210.00
growth rate 45.7% 0.0% -7.3% 0.0%
Inventory 58.40
53.20
53.20
61.00
61.00
growth rate -8.9% 0.0% 14.7% 0.0%
Cur.Liabilities 165.50
177.90
177.90
190.10
190.10
growth rate 7.5% 0.0% 6.9% 0.0%
Liabilities 331.20
315.50
315.50
249.90
249.90
growth rate -4.7% 0.0% -20.8% 0.0%
LT Debt
growth rate
Equity 979.90
989.20
989.20
914.70
914.70
growth rate 1.0% 0.0% -7.5% 0.0%
Common Shares 38.50
38.60
38.60
38.60
38.60
growth rate 0.3% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '17 Jun '17 Sep '17 Dec '17 Mar '18
Capital Expenditures 2.00
1.55
1.55
3.65
3.65
growth rate -22.5% 0.0% 135.5% 0.0%
Cash Dividends
growth rate
Cash From OA 6.70
39.40
39.40
20.95
20.95
growth rate 488.1% 0.0% -46.8% 0.0%
Sale Purchase of Stock 0.10
0.95
0.95
0.25
0.25
growth rate 850.0% 0.0% -73.7% 0.0%
FCF 4.70
37.85
37.85
17.30
17.30
growth rate 705.3% 0.0% -54.3% 0.0%
Income Statement Mar '17 Jun '17 Sep '17 Dec '17 Mar '18
Sales 142.55
170.65
170.65
139.60
139.60
growth rate 19.7% 0.0% -18.2% 0.0%
Op.Income 12.20
38.80
38.80
15.50
15.50
growth rate 218.0% 0.0% -60.1% 0.0%
IBT 10.25
23.60
23.60
-58.90
-58.90
growth rate 130.2% 0.0% -100.0% 0.0%
Net Income 10.35
26.65
26.65
-19.15
-19.15
growth rate 157.5% 0.0% -100.0% 0.0%
EPS
growth rate
Gross Profit 97.10
118.55
118.55
98.85
98.85
growth rate 22.1% 0.0% -16.6% 0.0%
R&D 25.00
23.05
23.05
25.35
25.35
growth rate -7.8% 0.0% 10.0% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (53.10)

YOY Growth Grade:

D (43.71)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 153.08 161.28 13.27
EPS / Growth 78.0% 0.04 15.5%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 13.2%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 13.2% 14.3% 14.3%
Future PE 13.27 20.95 20.95
Future EPS 0.13 0.15 0.15
Value Price
MOS %
0.44
-93.0%
0.77
-87.8%
0.77
-87.8%
MOS Price 0.22 0.39 0.39
IRT 24.14 22.81 22.81

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.